Loading…

Rezolute, Inc.RZLTCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum leader 80
Mkt cap
$411M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$6.97M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.3%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · USD$4.25
1D+5.8%
1W+4.4%
1M+14.9%
3M-8.8%
6M+32.0%
YTD+80.1%
1Y-58.4%
ATR %8.6%
Beta1.09
52w lowhigh61.9% off high

What Rezolute does

Employees: 58

Rezolute at a glance

Size Rezolute (RZLT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $411M, the 2814th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.25 on 18 Nov 2026.

Performance Over six months the shares gained 32.0%, against -21.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026RZLT 127Peer median 81
Six months, rebased to 100: Rezolute against the median of its 20 peers (local-currency closes).

Rezolute financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$31,000-$31,000-$31,000-$36,000-$382,000
EBITDA-$82.5M-$82.9M-$79.9M-$70.4M-$55.6M
Net income-$77.9M-$77.6M-$74.4M-$68.5M-$51.8M
Free cash flow-$66.0M-$64.6M-$69.1M-$57.4M-$44.6M
Capital expenditure$0$0$0$0$153,000
Total debt$754,000$934,000$1.61M$2.23M$2.48M

Quarterly statements and history in the cockpit →

Rezolute competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%7871CTMX0028646535000931002581002728603139TVGN0010606010894114048410300636OVIDZOTA600613002923PHAT219ARZLT6-month return →1-month return →
Up and to the right = strong over both horizons. Rezolute is the large dot.

Rezolute competitors and peer comparison

How Rezolute compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Rezolute against its 20 peers (data as of 18 Nov 2026)
MeasureRZLTPeer medianRank in peer set
1-month return+14.9%-10.6%highest of 21
6-month return+32.0%-21.3%3rd highest of 21
Distance from 52-week high-61.9%-44.1%6th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Rezolute RZLTUnited States$411M+32%n/an/an/an/an/a
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
CytomX Therapeutics CTMXUnited States$410M-49%-88%-676%4.7×n/an/a
Shaanxi Panlong Pharmaceutical 002864.SZChina$407M-15%-16%7%1.7×-3.2%+11.2%
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%

Questions

Which companies are Rezolute's closest peers?
The cockpit's peer set: Elixiron Immunotherapeutics (Cayman) (7871.TWO), CytomX Therapeutics (CTMX), Shaanxi Panlong Pharmaceutical (002864.SZ), Lumosa Therapeutics (6535.TWO), Beijing Centergate Technologies (Holding) (000931.SZ), Shandong Sinobioway Biomedicine (002581.SZ), Teyi Pharmaceutical (002728.SZ), Shaanxi Kanghui Pharmaceutical Co (603139.SS).
How has Rezolute stock performed?
Over six months to 18 Nov 2026 the shares returned +32.0% against -21.3% for the median peer; over one year -58.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.